Augurex CEO Neil Klompas describes why it is difficult for biomarkers to diagnose rheumatoid arthritis in some cases.

The prevalence of anti-citrullinated protein antibodies is low in patients with coronary artery disease without RA; in those with RA, C-reactive protein levels may explain the antibody-mortality link.

Explore the unique aspects of rheumatoid arthritis in men, including diagnosis, symptoms, complications, and support options ...

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with ...

Trial data suggest a JAK inhibitor beats the leading biologic ...

FDA grants Priority Review to sBLA for efgartigimod alfa-fcab for adults with AChR-Ab seronegative generalized myasthenia gravis.

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Could SGLT2 Inhibitors Reduce Rheumatoid Arthritis Flares? Two ACR 2025 analyses link SGLT2 inhibitors to fewer RA flares and a lower risk for osteoarthritis than GLP-1 receptor agonists, though ...

Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...